Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLC


In Partnership With:

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Pradnya D. Patil, MD, FACP, Hematology and Medical Oncology fellow, Cleveland Clinic, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer (NSCLC).

Identifying biomarkers that can better predict benefit with the use of immunotherapy in NSCLC remains one of the biggest unmet needs in this space, Patil says. Currently, PD-L1 and tumor mutational burden (TMB) are the best biomarkers available for identifying patients who could benefit from immunotherapy. However, these markers are not perfect, Patil notes. For example, there are still instances of patients with very high PD-L1 expression who do not respond to immunotherapy, Patil says. Therefore, in addition to learning more about PD-L1’s and TMB’s roles as a predictive biomarker, identifying other biomarkers from the tumor microenvironment is necessary, Patil says. Tumor infiltrating lymphocytes could represent one novel biomarker, and researchers must better understand what these biomarkers mean, and how to incorporate that information into day-to-day treatment algorithms, Patil emphasizes.

Another area of unmet need remains stems from primary resistance or acquired resistance to immunotherapy. A significant amount of research has already been conducted to better understand mechanisms of resistance; however, it is important to understand how to design clinical trials that will allow clinicians to combat that resistance, Patil notes.

Toxicities associated with immunotherapy are also an area of need for patients with NSCLC, Patil emphasizes. For immunotherapy-based combinations with novel agents, it is necessary to obtain a better understanding of biomarkers to identify patients who are at risk for toxicities and learn how to better manage these toxicities, Patil explains. Although there are national and international guidelines for immune related adverse effects, there's still a bit of variability and not a lot of high level evidence in clinical practice, Patil concludes.

Related Videos
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Abhishek Tripathi, MD, genitourinary medical oncologist, City of Hope
Pooja Advani, MBBS, MD, Mayo Clinic